Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal denervation - can we press the "ON" button again?

Jacek Kądziela1, Ewa Warchoł-Celińska2, Aleksander Prejbisz2

  • 1Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland.

Postepy W Kardiologii Interwencyjnej = Advances in Interventional Cardiology
|January 4, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redo-Transcatheter Aortic Valve Implantation (Redo-TAVI)-Pilot Study from Multicentre Nationwide Registry.

Journal of clinical medicine·2025
Same author

Treatment of Severe Tricuspid Regurgitation with the TricValve System Implantation-Preliminary Results of a Prospective Registry.

Journal of clinical medicine·2025
Same author

Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.

Journal of the American Heart Association·2025
Same author

Ischemic Complications in a Patient With Spontaneous Echo Contrast Undergoing Percutaneous Left Atrial Appendage Closure.

JACC. Case reports·2025
Same author

Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction.

Kardiologia polska·2025
Same author

Cardiology in Poland: A report for the year 2024 - part 2: Electrophysiology and device therapy.

Kardiologia polska·2025

Percutaneous renal denervation (RDN) for resistant hypertension shows evolving results. Recent trials with new devices suggest potential, but guidelines currently limit its use outside clinical studies.

Area of Science:

  • Cardiovascular Interventions
  • Hypertension Management
  • Medical Device Technology

Background:

  • Percutaneous renal denervation (RDN) emerged as a promising interventional treatment for resistant hypertension.
  • Initial trials showed positive outcomes, driving significant development in RDN technology.
  • The Symplicity HTN-3 trial raised questions about RDN's efficacy, leading to revised European guidelines in 2018.

Purpose of the Study:

  • To review the evolution of percutaneous renal denervation for resistant hypertension.
  • To discuss the impact of the Symplicity HTN-3 trial and subsequent guideline changes.
  • To present results from recent RDN trials and discuss future research directions.

Main Methods:

  • Review of published clinical trials on percutaneous renal denervation.
Keywords:
renal denervationresistant hypertensionreview

Related Experiment Videos

  • Analysis of outcomes from recent studies including SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, RADIANCE-HTN SOLO, and RADIOSOUND-HTN.
  • Inclusion of data from studies involving patients with obstructive sleep apnea.

    • Main Results:

    • The Symplicity HTN-3 trial's results led to a re-evaluation of RDN's role in resistant hypertension treatment.
    • Newer generation devices and recently published trials show varied but potentially improved outcomes.
    • Studies in patients with obstructive sleep apnea are also being considered.

    Conclusions:

    • Current European guidelines recommend against device-based therapies for hypertension outside of clinical trials.
    • Upcoming large trials like SPYRAL PIVOTAL and RADIANCE II are expected to provide further clarity on RDN's efficacy.
    • Further research and large-scale trials are necessary to establish the definitive role of RDN in hypertension management.